Annaida Technologies successfully closed an oversubscribed Pre-Series A funding round to develop its groundbreaking micro-magnetic resonance technology for fertility and life science applications.

Target Information

Annaida Technologies Srl, based in Lausanne, Switzerland, is the world's pioneer in miniaturizing magnetic resonance imaging to a cellular scale. The company has recently completed a successful oversubscribed Pre-Series A funding round to further develop its innovative micro-magnetic resonance platform.

Leading the financing round was HEMEX, alongside participation from existing investors including Zürcher Kantonalbank (ZKB), Excellis, EFI Lake Geneva Ventures, and members of the Investors Club through Simon Fiduciaria. The combined capital raised, augmented by grants from European programs such as EIC Transition (Horizon Europe) and Innosuisse (Swiss Innovation Project), bolsters Annaida's position in preparing its groundbreaking technology for the market.

Industry Overview

The fertility industry in Switzerland, and broadly in Europe, has been facing a steady decline in fertility rates, a trend influenced by various social changes